Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track

Black Diamond Therapeutics, Inc.

2024-Q2 EPS reported -$0.71

Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.
Net loss $19.9M in Q2 2024 vs $19.2M in Q2 2023; R&D expenses decreased to $12.6M from $13.2M.
Initial Phase 2 data for BDTX-1535 in 2L/3L EGFRm NSCLC on track for later Q3 2024; 1L data in Q1 2025.
Initial Phase 1 data for BDTX-4933 in KRASm NSCLC on track for Q4 2024; ESMO poster in September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.